Abraxis BioScience
| Industry | Pharmaceutical |
|---|---|
| Founded | 2007 in Los Angeles, California |
| Founder | Dr. Patrick Soon-Shiong |
| Headquarters | Los Angeles , USA |
Key people | Mr. Rick Click, Chief Information Officer and Global IT Officer; Dr. Nguyen V. Dat Ph.D., Vice President of Clinical Research |
| Products | Protein-based therapeutics and technologies for treatment of cancer and other critical illnesses |
| Brands | Abraxane |
| Services | Cancer drugs |
| Owner | Celgene |
| Website | www |
Abraxis BioScience is a global biopharmaceutical company dedicated to meeting the needs of critically ill patients, with over 2000 employees worldwide.[1] Abraxis' portfolio includes the world's first protein-based nanoparticle chemotherapeutic compound called nab Technology.[2] From this the company has developed Abraxane, a treatment for metastatic breast cancer.[3] On June 30, 2010, it was announced that Abraxis BioScience would be acquired by Celgene Corporation.[4]
History
Restructure of 2007
In August 2007, Abraxis announced it would undergo a restructuring to separate it's "hospital-based products business" from its "proprietary products business" into two public companies; this would involve the merging of Abraxis Oncology and Abraxis Research subunits to form a new Abraxis Bioscience (Abraxis Bioscience, Inc., Nasdaq: ABII), and the spinoff of Abraxis Pharmaceutical Products (APP, Inc., Nasdaq: APPX).[5] This reorganization was completed in November 2007.[6] During the reorganization, the new Abraxis Bioscience was known briefly as "New Abraxis".[6]
References
- ^ BioPortfolio, 2007, "InDepth Summary", 10/11/2009[dead link]
- ^ Abraxis BioScience, 2008, "Nab Technology", 10/11/2009
- ^ Hoovers.[dead link]
- ^ Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.
- ^ Van Arnum, Patricia (1 August 2007). "Abraxis BioScience Plans to Separate into Two Companies". Pharmaceutical Technology. Retrieved 2015-08-07 – via Highbeam Research.
- ^ a b Gopalakrishnan, Lisa (13 November 2007). FORM 8-K (Report). United States Securities and Exchange Commission. Retrieved 2015-08-07.
External links
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |